Welcome to our dedicated page for Bioadaptives news (Ticker: BDPT), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
BioAdaptives, Inc. (BDPT) news covers the company’s activity in nutraceuticals, nootropics, weight management, and pet wellness. Recent announcements highlight product launches, clinical milestones, and third-party validations that shape BioAdaptives’ position in the health and wellness market.
Investors and followers can track updates on MyndMed™, a cognitive-support dietary supplement formulated to aid memory, focus, and mental clarity. News items describe its commercial launch, manufacturing in cGMP-certified facilities, third-party testing, and clearance from TruShield™ Laboratory Services confirming compliance with World Anti-Doping Agency (WADA) standards, which is particularly relevant for competitive athletes and sports organizations.
Coverage also includes developments around NeuroRush™, an adaptogenic nootropic intended to support cognitive performance and stress resilience, and Zeranovia™, a weight management product undergoing IRB-approved human clinical trials and dosage studies. These updates provide insight into BioAdaptives’ research progress, trial outcomes, and product rollout plans.
On the pet wellness side, news features the PawPa™ division and products such as Pawpa™ Regen and Regen Dog Chews, which are described as supporting stem cell activation and regenerative healing in aging dogs. Articles detail veterinarian trials, the APBAR® rating system, and national launch plans.
Visitors to this BDPT news page can review company press releases regarding leadership appointments, advisory board additions, and strategic direction, alongside product-focused announcements. For those monitoring the nutraceutical and wellness sector, this feed offers a centralized view of BioAdaptives’ latest product introductions, clinical steps, and validation efforts.
BioAdaptives Inc. (OTCMkts: BDPT) announces the launch of MindnMemory, a nootropic aimed at enhancing memory, focus, and mental clarity, particularly benefiting seniors and e-Gamers. This stimulant-free formulation is rooted in Traditional Chinese Medicine and aims to avoid the sudden highs and crashes typical of caffeine. The global nootropic market surpassed $10.5 billion in 2021 and is projected to hit $31 billion by 2029, growing at 18% annually. CEO Edward Jacobs highlights that MindnMemory promotes sustained mental performance through increased mitochondrial energy production.
BioAdaptives, Inc. (OTCMkts: BDPT) has launched a new line of enhanced nutraceuticals for holistic healthcare practitioners, targeting symptoms associated with COVID-19 aftermath like brain fog and fatigue. The U.S. alternative medicine market is valued at approximately $21 billion, serving over one million healthcare professionals. CEO Dr. Edward Jacobs highlighted the products' neuro-protective, anti-viral, and calming properties. While the current product lineup includes popular items like PluriPain® and PrimiSleep™, new “Nu” branded offerings aim to meet increasing practitioner demand. None of the claims have FDA approval.
BioAdaptives, Inc. (OTCMkts: BDPT) has launched PrimiSleep™, a natural sleep supplement developed to promote relaxation and uninterrupted sleep without cognitive impairment. The product is based on Traditional Chinese Medicine and Ayurvedic principles, addressing the increasing demand for effective sleep solutions, particularly as chronic sleep issues affect over 70 million Americans. The global sleeping aids market is projected to grow from $64 billion in 2021 to $118 billion by 2030, with a CAGR of 7.1%. CEO Edward Jacobs highlights the importance of optimal sleep for overall health.
BioAdaptives, Inc. (OTCMkts: BDPT) has introduced a cost-effective wellness combination package featuring PluriPain®, PrimiLungs™, and PrimiSleep™ to address increased consumer demand for solutions to chronic symptoms. These products may help manage issues like brain fog, pain, and sleep disturbances, particularly in those affected by COVID-19. Each formula is designed to provide specific benefits, and together they are reported to enhance well-being. The introductory package is available for a nominal fee, allowing consumers to experience the synergistic effects firsthand.
BioAdaptives, Inc. (OTCMkts: BDPT) has launched the Canine All-in-One, an advanced daily supplement for dogs, modeled after its successful horse supplement, Equine All-in-One. This product combines the Canine Regen with natural ingredients to address various health issues while reducing the need for multiple supplements. Dog owners report rapid improvements in older dogs’ energy, recovery, and mobility. The global pet supplement market is projected to grow, indicating strong demand for such products. Canine All-in-One is based on eight years of success and safety without adverse effects.
BioAdaptives, Inc. (BDPT) announces a new program aimed at helping seniors afford their advanced nutraceutical supplements amidst rising inflation. The initiative offers discounts for single-container purchases, reducing prices from $59.95-$69.95 to $29.95-$39.95. This strategy is expected to tap into the growing nutraceutical market, projected to reach USD 454.55 billion by 2030, with a CAGR of 9.0%. CEO Edward Jacobs emphasized the importance of making health-related products accessible for seniors, particularly in light of COVID-related health issues and rising living costs.
Summary not available.
Summary not available.
BioAdaptives, Inc. (OTCMkts: BDPT) announced positive results from a study led by Dr. Lorrin Koran at Stanford Medical School on Pluripain® for Gadolinium Deposition Disease (GDD). The study revealed that 60% of participants experienced significant relief from pain and brain fog. Pluripain® is suggested to reduce opioid dependency in patients. The CEO of BioAdaptives expressed optimism about further studies confirming the supplement's benefits. GDD arises from excessive gadolinium build-up from MRIs, affecting certain patients.
BioAdaptives, Inc. (OTCMkts: BDPT) has acquired U.S. Patent 9,783,432B from inventor Thomas J. Mohr to enhance oxygen capacity in water. This technology embeds oxygen molecules, offering long-term aerobic benefits for performance and health. The company is forming MORO2, Inc. to develop consumer products based on this technology, with marketing set to begin in 2Q 2022. Under the agreement, BioAdaptives holds exclusive rights for two years and has engaged Mohr as a consultant. This acquisition positions the company for growth in nutraceutical-enhanced oxygenated water products.